Overview

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Status:
RECRUITING

Trial end date:
2031-12-31

Target enrollment:

Participant gender:

Summary

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

Phase:

PHASE3

Details

Lead Sponsor:

Relay Therapeutics, Inc.

Treatments:

capivasertib
Fulvestrant